The Journal of Rheumatology: 65

September 01, 2002; Volume 65,

Comparing Biologic Therapies in RA: Making Sense of the Data, and Inflammation and Bone Resorption in Rheumatoid Arthritis: Understanding the Underlying Mechanisms

You have access
The pathogenesis of rheumatoid arthritis: pivotal cytokines involved in bone degradation and inflammation.
Clifton O Bingham 3rd

The Journal of Rheumatology Supplement September 1 2002, 65 3-9;
You have access
Interleukin 1 or tumor necrosis factor-alpha: which is the real target in rheumatoid arthritis?
Jean-Michel Dayer

The Journal of Rheumatology Supplement September 1 2002, 65 10-15;
You have access
The mode of action of cytokine inhibitors.
William P Arend

The Journal of Rheumatology Supplement September 1 2002, 65 16-21;
You have access
Tides of inflammation: impact of biologics.
E William St Clair

The Journal of Rheumatology Supplement September 1 2002, 65 22-26;
You have access
Examining the efficacy of biologic therapy: are there real differences?
Roy M Fleischmann

The Journal of Rheumatology Supplement September 1 2002, 65 27-32;
You have access
What are the risks of biologic therapy in rheumatoid arthritis? An update on safety.
Michael H Weisman

The Journal of Rheumatology Supplement September 1 2002, 65 33-38;
You have access
Preventing joint damage as the best measure of biologic drug therapy.
Barry Bresnihan

The Journal of Rheumatology Supplement September 1 2002, 65 39-43;
You have access
Bone and joint destruction in rheumatoid arthritis: what is really happening?
Steven R Goldring

The Journal of Rheumatology Supplement September 1 2002, 65 44-48;